GTCb - diese Woche Zulassung in Europa - 500 Beiträge pro Seite

[isis32]

Heute schoen 24% hoch nach Bericht on CBS Hauptnachrichten- sendung.

http://www.cbsnews.com/sections/i_video/main500251.shtml?cha…

videolink:

Life-Saving Goats

Zulassung in Europa steht noch diese Woche an?

Also ich bin drin

Isis

[mfierke]

[M.Haze]

Moin,

hab die schon seit Jahren - einer der beiden verbliebenen Biotechs bei mir.

Man kann zwar sagen, was soll der Umstand mit Ziegen, Wirkstoffe mit Bakterien produzieren ist einfacher und billiger in der Entwicklung, aber: Ziege bleibt Ziege, für Bakterien brauch man ein Labor, ne Ziege steht im Garten
Das geht dann so ab:
Ey Kollege, meine Ziege produziert krasses Medikament in Milch, willsdu kaufen, schlappe 10.000 Scheine Kollege

mh

[M.Haze]

AP
GTC Biotherapeutics Up on Panel Decision
Friday June 2, 9:42 am ET
GTC Biotherapeutics Shares Soar As EU Advisory Panel Recommends Drug Approval


FRAMINGHAM, Mass. (AP) -- Shares of GTC Biotherapeutics Inc. soared Friday after announcing that a European advisory panel recommended that regulators approve the biotech drug maker's ATryn therapy.
GTC shares shot up 91 cents, or nearly 93 percent, to $1.89 in early morning trading on the Nasdaq. Shares of GTC have traded between 87 cents and $2.41 over the past 52 weeks.

The company said the Committee for Medicinal Products for Human Use recommended that the European Agency for the Evaluation of Medicinal Products approve the use of ATryn to prevent blood clots in patients who lack natural blood thinners.

The EMEA should rule on whether or not to approve the drug in three months.

GTC intends to use data review by the panel and results from an ongoing late-stage clinical trial to file an application for ATryn with the Food and Drug Administration.

[M.Haze]

Yahoo! My Yahoo! Mail Make Yahoo! your home page
Sign In
New User?Sign Up
Finance Home - Help



HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search



Press Release Source: GTC Biotherapeutics, Inc.


ATryn(R) Receives CHMP Recommendation to Grant Market Authorization
Friday June 2, 7:12 am ET
Indicated for Prophylactic Treatment of Hereditary Antithrombin Deficient Patients Undergoing Surgery


FRAMINGHAM, Mass.--(BUSINESS WIRE)--June 2, 2006--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion on the market authorization application (MAA) for ATryn®, GTC's recombinant form of human antithrombin. The CHMP has recommended that ATryn® be granted market authorization for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. ATryn® may be given in association with heparin or low molecular weight heparin in these situations. The CHMP opinion recommends granting market authorization under the EMEA's procedures for exceptional circumstances. Final market authorization by the European Commission is expected in about three months. The positive CHMP opinion followed a defined process this week that included a review of GTC's submission of the grounds supporting re-examination of the previous opinion as well as a review of responses to specific questions posed by the CHMP to an independent expert panel composed of internationally recognized experts in the fields of hematology and hemostasis. These review activities are an integral part of the regulatory process for re-examination of a prior opinion.
Source: GTC Biotherapeutics, Inc.


· GTC Biotherapeutics' ATryn(R) Product (Photo: Business Wire). View Multimedia Gallery




Upon approval, ATryn® will be the first antithrombin product approved for use in all 25 countries of the European Union. ATryn® will also be the only available antithrombin product that is produced by recombinant biotechnology and is not derived from the human blood supply.

Professor Isobel Walker, Consultant Haematologist, Glasgow Royal Infirmary, comments that, "It is a good day for European patients with congenital antithrombin deficiency and for their physicians. ATryn® provides an alternative to treatment with human plasma derived antithrombin and gives physicians and patients more choice in how they will be treated."

"Today's announcement marks a very significant achievement for GTC, being the first company to obtain a positive regulatory opinion on the commercial use of a therapeutic protein that is produced transgenically," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "ATryn® presents an opportunity for hereditary deficiency patients in Europe to choose an antithrombin product that has met the rigorous examination and review requirements of the centralized EMEA procedures for recombinant proteins. The dedication and perseverance of our employees have been instrumental in GTC reaching this point. We look forward to working with our European partner, LEO Pharma A/S, to begin the activities required to launch this product in the marketplace and to support the further development of ATryn® for the treatment of DIC associated with severe sepsis. The positive opinion is also very supportive of the continuing development of ATryn® in our ongoing study of the hereditary deficiency indication for a regulatory submission in the United States. This opinion marks an important step in our strategy to advance the significant commercial opportunity which we believe ATryn® offers and to unlock the value of our transgenic technology for the production of therapeutic proteins."

GTC anticipates using the results from both the completed study reviewed by the CHMP and GTC's ongoing pivotal phase III study to prepare a Biologics License Application for the United States Food and Drug Administration. The results of the pivotal phase III study will also be submitted for consideration by the CHMP for expansion of the use of ATryn® in Europe to prevent deep vein thromboses and thromboembolisms in women with a hereditary antithrombin deficiency who are undergoing childbirth.

Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties. LEO Pharma has also begun development of ATryn® in Europe as a potential treatment for disseminated intravascular coagulation, or DIC, associated with severe sepsis. DIC occurs in an estimated 220,000 severe sepsis cases in the European Union each year, of which approximately 50% are fatal, representing a major unmet medical need of significant interest in critical care.

About GTC Biotherapeutics, Inc.

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to the ATryn® program, GTC has in development a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of GTC's external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.

[M.Haze]

sorry, posting #5 sollte nur den letzten Abschnitt 'About Genzyme Transgenics' enthalten.